Content deleted Content added
changed chembl id |
86.29.57.38 (talk) No edit summary |
||
Line 53: | Line 53: | ||
It is usually administered as the disodium salt. Balsalazide releases [[mesalazine]], also known as 5-aminosalicylic acid, or 5-ASA,<ref>{{cite pmid|11709512}}</ref> in the large intestine. Its advantage over that drug in the treatment of [[ulcerative colitis]] is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. |
It is usually administered as the disodium salt. Balsalazide releases [[mesalazine]], also known as 5-aminosalicylic acid, or 5-ASA,<ref>{{cite pmid|11709512}}</ref> in the large intestine. Its advantage over that drug in the treatment of [[ulcerative colitis]] is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. |
||
==Synthesis== |
|||
[[File:Balsalazide synthesis.png|thumb|center|600px|Balsalazide synthesis: Biorex Laboratories, {{Cite patent|GB|2080796}} (1986).]] |
|||
#Starting material is 4-amino[[hippuric acid]], obtained by coupling [[para-aminobenzoic acid]] and [[glycine]]. |
|||
#That product is then treated with [[nitrous acid]] to give the [[diazonium salt]]. |
|||
#Reaction of this species with [[salicylic acid]] proceeds at the position para to the phenol to give balsalazide. |
|||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
Revision as of 07:42, 22 October 2014
Clinical data | |
---|---|
Trade names | Colazal, Giazo |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699052 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | <1% |
Protein binding | ≥99% |
Elimination half-life | 12hr |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.117.186 |
Chemical and physical data | |
Formula | C17H15N3O6 |
Molar mass | 357.318 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names "Giazo", "Colazal" in the US and "Colazide" in the UK. It is also sold in generic form in the US by several generic manufacturers.
It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
Synthesis
- Starting material is 4-aminohippuric acid, obtained by coupling para-aminobenzoic acid and glycine.
- That product is then treated with nitrous acid to give the diazonium salt.
- Reaction of this species with salicylic acid proceeds at the position para to the phenol to give balsalazide.
References
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11709512, please use {{cite journal}} with
|pmid=11709512
instead.